Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data

biotech lab

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).

gMG is a rare, chronic autoimmune disease that causes weakness in voluntary muscles, affecting the eyes, face, neck, arms, legs, and breathing.